Guaifenesin-Dextromethorphan Dosing
The standard dose strength for guaifenesin-dextromethorphan (DM) taken twice daily is guaifenesin 200 mg/dextromethorphan 20 mg per 10 mL, administered as 10 mL (one unit dose cup) twice daily for 10 days. 1
FDA-Approved Formulations
The FDA-approved formulation provides two concentration options 1:
- 5 mL formulation: Guaifenesin 100 mg + Dextromethorphan 10 mg per 5 mL
- 10 mL formulation: Guaifenesin 200 mg + Dextromethorphan 20 mg per 10 mL
For BID (twice daily) dosing over 10 days, the 10 mL unit dose cup is the standard preparation, delivering 200 mg guaifenesin and 20 mg dextromethorphan per dose 1.
Clinical Context and Evidence Limitations
Important Caveats About This Combination
While this combination is widely available and FDA-approved, the evidence supporting its efficacy is mixed:
Dextromethorphan: Studies show variable results. Some trials demonstrated 19-50% reduction in cough counts at 30-60 mg doses 2, while others showed no significant difference from placebo in cough frequency or severity 2. The 20 mg dose in this formulation is below the 30 mg threshold where some studies showed benefit.
Guaifenesin: Recent evidence questions its expectorant efficacy, with studies showing no significant benefits over placebo for upper respiratory disease 3. A 1993 trial found guaifenesin alone equally effective as guaifenesin plus codeine or dextromethorphan, suggesting minimal additive benefit 4.
Guideline Perspective
The 2006 CHEST guidelines specifically state: "over the counter combination cold medications, with the exception of an older antihistamine-decongestant, are not recommended until randomized controlled trials prove that they are effective cough suppressants" 2. This recommendation carries a Grade D (benefit: none) rating.
Practical Dosing Algorithm
If prescribing this combination despite limited evidence:
- Administer 10 mL (200 mg/20 mg) twice daily
- Maximum duration: 10 days as specified
- Take with or without food
- Ensure adequate hydration
Consider alternatives given the weak evidence base, particularly for chronic or unexplained cough where multimodality speech pathology therapy (Grade 2C) or neuromodulators like gabapentin show stronger evidence 5.